ICU Medical, Inc. (ICUI) Reaches $274.93 High on May, 18; Kinross Gold (TSE:K) Covered By 3 Bullish Analysts Last Week

May 18, 2018 - By Peter Erickson

ICU Medical, Inc. (NASDAQ:ICUI) Logo

The stock of ICU Medical, Inc. (NASDAQ:ICUI) reached all time high today, May, 18 and still has $294.17 target or 7.00% above today’s $274.93 share price. This indicates more upside for the $5.58B company. This technical setup was reported by Barchart.com. If the $294.17 PT is reached, the company will be worth $390.74 million more. The stock increased 0.28% or $0.775 during the last trading session, reaching $274.925. About 41,755 shares traded. ICU Medical, Inc. (NASDAQ:ICUI) has risen 61.26% since May 18, 2017 and is uptrending. It has outperformed by 49.71% the S&P500.




Among 6 analysts covering Kinross Gold Corporation (TSE:K), 3 have Buy rating, 1 Sell and 2 Hold. Therefore 50% are positive. Kinross Gold Corporation had 23 analyst reports since September 1, 2015 according to SRatingsIntel. Scotia Capital maintained it with “Sector Perform” rating and $4 target in Friday, February 17 report. Desjardins Securities maintained the shares of K in report on Monday, December 11 with “Sell” rating. Scotia Capital maintained it with “Sector Perform” rating and $4 target in Friday, May 5 report. The stock of Kinross Gold Corporation (TSE:K) earned “Neutral” rating by JP Morgan on Thursday, February 4. Scotia Capital maintained it with “Sector Perform” rating and $8.50 target in Thursday, November 3 report. The stock of Kinross Gold Corporation (TSE:K) earned “Outperform” rating by RBC Capital Markets on Friday, August 26. BMO Capital Markets upgraded the shares of K in report on Monday, May 29 to “Outperform” rating. The company was upgraded on Tuesday, November 24 by RBC Capital Markets. RBC Capital Markets maintained Kinross Gold Corporation (TSE:K) rating on Friday, September 23. RBC Capital Markets has “Outperform” rating and $10 target. See Kinross Gold Corporation (TSE:K) latest ratings:

11/12/2017 Broker: Desjardins Securities Rating: Sell Maintain

The stock increased 0.22% or $0.01 during the last trading session, reaching $4.57. About 468,247 shares traded. Kinross Gold Corporation (TSE:K) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Since December 13, 2017, it had 0 insider buys, and 8 sales for $165.23 billion activity. $9.51M worth of Kinross Gold Corporation (TSE:K) was sold by KELLOGG W K FOUNDATION TRUST on Friday, March 2.

Investors sentiment increased to 0.91 in Q4 2017. Its up 0.05, from 0.86 in 2017Q3. It increased, as 60 investors sold Kinross Gold Corporation shares while 212 reduced holdings. 82 funds opened positions while 166 raised stakes. 309.07 million shares or 0.67% more from 307.00 million shares in 2017Q3 were reported. Massmutual Trust Fsb Adv reported 113,557 shares. Willingdon Wealth Mngmt holds 0% of its portfolio in Kinross Gold Corporation (TSE:K) for 68 shares. Ent Fin owns 2,209 shares for 0.07% of their portfolio. Hudock Capital Llc has 0.02% invested in Kinross Gold Corporation (TSE:K). Diversified Tru Co owns 6,475 shares. Bancshares Of New York Mellon Corporation holds 0.08% of its portfolio in Kinross Gold Corporation (TSE:K) for 4.24 million shares. Creative Planning holds 0.01% in Kinross Gold Corporation (TSE:K) or 18,121 shares. Dillon And Assoc has 9,820 shares for 0.25% of their portfolio. Schmidt P J Invest Management reported 3,067 shares or 0.06% of all its holdings. Vanguard Grp holds 0.07% of its portfolio in Kinross Gold Corporation (TSE:K) for 22.58M shares. Martingale Asset Mgmt Limited Partnership stated it has 0.26% of its portfolio in Kinross Gold Corporation (TSE:K). 2,521 were reported by Bartlett & Ltd. Argi Ser Ltd holds 0.01% or 3,292 shares. New York-based Canandaigua Comml Bank Tru has invested 0.16% in Kinross Gold Corporation (TSE:K). Sei Invs Company invested 0.02% in Kinross Gold Corporation (TSE:K).

Kinross Gold Corporation, together with its subsidiaries, engages in the acquisition, exploration, and development of gold properties. The company has market cap of $5.71 billion. The companyÂ’s gold production and exploration activities are carried out principally in Canada, the United States, the Russian Federation, Brazil, Chile, Ghana, and Mauritania. It has a 13.06 P/E ratio. It also produces and sells silver; and explores for copper.

Analysts await ICU Medical, Inc. (NASDAQ:ICUI) to report earnings on August, 8. They expect $1.45 earnings per share, up 178.85% or $0.93 from last year’s $0.52 per share. ICUI’s profit will be $29.44M for 47.40 P/E if the $1.45 EPS becomes a reality. After $2.06 actual earnings per share reported by ICU Medical, Inc. for the previous quarter, Wall Street now forecasts -29.61% negative EPS growth.

ICU Medical, Inc. develops, manufactures, and sells medical devices used in infusion therapy, critical care, and oncology applications worldwide. The company has market cap of $5.58 billion. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patientÂ’s vein for use in hospitals and ambulatory clinics. It has a 83.56 P/E ratio. The companyÂ’s infusion therapy products include needlefree connector products, such as MicroClave and MicroClave Clear, Neutron, NanoClave, Clave, and SwabCap; custom infusion sets; and Tego needlefree hemodialysis connectors.

More notable recent ICU Medical, Inc. (NASDAQ:ICUI) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: AstraZeneca’s Q1, Novartis-Amgen Migraine Drug Approved” on May 18, 2018, also Globenewswire.com with their article: “ICU Medical, Inc. Announces First Quarter 2018 Results” published on May 09, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” on May 17, 2018. More interesting news about ICU Medical, Inc. (NASDAQ:ICUI) were released by: Seekingalpha.com and their article: “ICU Medical’s (ICUI) CEO Vivek Jain on Q1 2018 Results – Earnings Call Transcript” published on May 10, 2018 as well as Ocbj.com‘s news article titled: “Midday Stock Roundup” with publication date: May 10, 2018.

Since January 4, 2018, it had 0 buys, and 9 insider sales for $31.12 million activity. $6.53M worth of ICU Medical, Inc. (NASDAQ:ICUI) was sold by LOPEZ GEORGE A on Monday, April 2. 1,566 shares were sold by SAUCEDO JOSEPH R, worth $421,285 on Monday, May 14. SWINNEY ROBERT S had sold 724 shares worth $170,140 on Friday, January 19. 23,624 shares were sold by Lamb Scott E, worth $5.20M. The insider Sanzone Virginia Ruth sold $134,925.

Among 5 analysts covering ICU Medical (NASDAQ:ICUI), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. ICU Medical had 11 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Roth Capital on Tuesday, August 11 with “Buy”. TH Capital maintained the stock with “Buy” rating in Friday, November 6 report. As per Wednesday, August 9, the company rating was maintained by Roth Capital. As per Tuesday, August 11, the company rating was maintained by Piper Jaffray. Gabelli initiated ICU Medical, Inc. (NASDAQ:ICUI) on Friday, March 11 with “Buy” rating. As per Friday, November 6, the company rating was maintained by Roth Capital. TH Capital maintained ICU Medical, Inc. (NASDAQ:ICUI) on Tuesday, August 11 with “Buy” rating. The rating was maintained by Gabelli on Friday, August 11 with “Buy”. The firm has “Hold” rating given on Monday, August 17 by Zacks.

ICU Medical, Inc. (NASDAQ:ICUI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: